... inhibitor sunitinib in patients with advanced or metastatic renal cell carcinoma (a/mRCC) in a real-world setting. Methods: We analyzed data of adult a/mRCC patients treated with sunitinib. Data were derived from the German non-interventional post-approval multicenter STAR-TOR registry (NCT00700258...

...Kojiro Ohba; Yasuyoshi Miyata; Kensuke Mitsunari; Tsuyoshi Matsuda; Yuta Mukae; Yuichiro Nakamura; Tomohiro Matsuo; Hideki Sakai Introduction: We investigated the efficacy and safety of every-other-day dosing of sunitinib for the treatment of metastatic renal cell carcinoma (mRCC) with extended...

...Martin Schostak; Patrick de Geeter; Thomas Decker; Anna Resch; Claudia Quiering; Stephan Schmitz Introduction: Sunitinib and pazopanib are both standard first-line therapies for clear-cell metastatic renal-cell carcinoma (mRCC). Everolimus is a well-established second-line treatment. Objective...

...Wen Cai; Jiwei Huang; Yichu Yuan; Xiaoyi Hu; Mingyang Li; Wen Kong; Jin Zhang; Jianming Guo; Yonghui Chen; Yiran Huang Objectives: The purpose of this work was to investigate the effect of sorafenib or sunitinib as neoadjuvant therapy on the survival outcomes of renal cell carcinoma (RCC...

...Tae Joon Lim; Jee Han Lee; Sung-Goo Chang; Choong Hyun Lee; Gyeong Eun Min; Koo Han Yoo; Seung Hyun Jeon Adverse events associated with sunitinib, such as cardiac toxicities, renal damage, and hemostatic complications, are well known. The authors report 3 cases in which patients experienced severe...

...Alaaeldin Shablak; Jackie O’Dwyer; Robert Hawkins; Ruth Board Metastatic renal cell carcinoma (mRCC) is a difficult to treat malignancy and currently Sunitinib is a standard of care first-line therapy. A new metastasis during the treatment is considered a sign of drug failure and alternative...

...Yao Zhu; Hui Li; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Guo-Hai Shi; Li-Feng Yang; Zhong-Yi Yang; Chao-Fu Wang; Ding-Wei Ye Introduction: We describe our experience with sorafenib and sunitinib in the treatment of chemotherapy-refractory advanced penile squamous cell carcinoma (SCC). Patients...

...Thomas Powles; Simon Chowdhury; Mark Bower; Nataile Saunders; Louise Lim; Jonathan Shamash; Naveed Sarwar; Anju Sadev; John Peters; James Green; Katia Boleti; Samir Augwal Background: Sunitinib is standard first-line therapy for metastatic clear cell renal cancer (MCRC). It is associated...

...Michael Staehler; Nicolas Haseke; Katja Zilinberg; Thomas Stadler; Christian G. Stief A 74-year-old man with metastatic renal cell carcinoma and a history of cardiac failure was treated with sunitinib malate. MUGA echocardiography could not detect a relevant change in the ejection fraction although...

...Hao Zeng; Xiang Li; Jin Yao; Yuchun Zhu; Jiyan Liu; Yuru Yang; Wei Qiang We report the case of a 70-year-old man who received sunitinib treatment for brain metastatic clear cell renal cell carcinoma. After 6 months of treatment, brain MRI showed complete disappearance of two brain metastases...

... with sunitinib was initiated and a notable response achieved. 24 07 2008 28 10 2008 27 7 2009 © 2009 S. Karger AG, Basel 2009 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Renal cancer Thrombus Sunitinib Urologia Internationalis Case Report Urol Int 2008;80...